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Abstract
CXCR4 and CXCR7 are the two receptors for the chemokine CXCL12, a key mediator of the growth effect of estrogens (E2) in
estrogen receptor (ER)-positive breast cancers. In this study we examined E2-regulation of the CXCL12 axis components and
their involvement in the growth of breast cancer cells. CXCR4 and CXCR7 were differentially regulated by E2 which
enhanced the expression of both CXCL12 and CXCR4 but repressed the expression of CXCR7. Formaldehyde-associated
isolation of regulatory elements (FAIRE) revealed that E2-mediated transcriptional regulation of these genes is linked to the
control of the compaction state of chromatin at their promoters. This effect could be accomplished via several distal ER-
binding sites in the regions surrounding these genes, all of which are located 20–250 kb from the transcription start site.
Furthermore, individual down-regulation of CXCL12, CXCR4 or CXCR7 expression as well as the inhibition of their activity
significantly decreases the rate of basal cell growth. In contrast, E2-induced cell growth was differentially affected. Unlike
CXCR7, the inhibition of the expression or activity of either CXCL12 or CXCR4 significantly blunted the E2-mediated
stimulation of cellular growth. Besides, CXCR7 over-expression increased the basal MCF-7 cell growth rate and decreased
the growth effect of E2. These findings indicate that E2 regulation of the CXCL12 signaling axis is important for the E2-
mediated growth effect of breast cancer cells. These data also provide support for distinct biological functions of CXCR4 and
CXCR7 and suggest that targeting CXCR4 and/or CXCR7 would have distinct molecular effects on ER-positive breast tumors.
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Introduction
Estrogens, notably 17-b-estradiol (E2), play a crucial role in the
control of epithelial cell proliferation and the differentiation of
normal mammary gland cells as well as in breast carcinomas. The
effects of E2 are mediated principally by nuclear estrogen
receptors alpha (ERa) and beta (ERb). ERa is expressed in 70%
of diagnosed breast cancers [1,2]. In ER-positive breast cancer
cells, E2 stimulates cell growth and plays a role in cancer
progression [3]. The proliferative effect of E2 can be repressed
using anti-estrogens used clinically in hormono-therapy [4].
Moreover, ER-positive breast tumors appear to be more
differentiated and appear to metastasize less than ER-negative
breast tumors [5,6]. Thus, the expression of ERa in breast tumors
is generally considered to be an indicator for a good prognosis.
Although recent works reported that the expression of many
genes are regulated by E2 in ER-positive breast cancer cells, little
is known about their role in E2-growth effect [3,7]. The
chemokine CXCL12 (also named SDF-1 for Stromal-cell Derived
Factor 1) was identified as a key mediator of E2-induced breast
cancer cell proliferation and survival [8,9]. This chemokine has
several well-known functions: (i) in cell migration during
embryonic development, (ii) in the chemotactism of circulating
leucocytes and (iii) in the homing of hematopoietic stem cells in
bone marrow niches [10,11]. Moreover, CXCL12 regulates the
homeostasis, angiogenesis, proliferation, survival and migration of
cancer cells [12,13,14]. The G Protein-Coupled-Receptor (GPCR)
CXCR4, an E2 endogenous target in endometrial cancer cells
[15], binds CXCL12. The high expression of CXCR4 has been
often associated with an invasive and migratory phenotype of
cancer cells [16,17]. Metastatic breast tumor cells highly
expressing CXCR4 are generally found in organs such as liver,
lung or bone. This suggests a privileged homing, survival and
proliferation of metastatic breast cancer cells to these specific sites,
where the local secretion of CXCL12 is strong [12,18,19].
Knockdown of CXCR4 by siRNA or blockage of CXCL12
binding with a CXCR4 specific neutralizing antibody or specific
CXCR4 inhibitors impairs the proliferation and migration
potential of these metastatic cells [19,20].
Until recently, the ligand/receptor couple CXCL12/CXCR4
was thought to be exclusive because cxcl12 2/2 and cxcr4 2/2
mice had similar prenatal lethal phenotypes [21]. CXCL12,
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RDC1 [22,23]. Growing evidence indicates a role for CXCR7 in
cancer cell proliferation and migration [24,25,26,27]. The relative
expression levels of CXCR4 and CXCR7 may be critical to
determine how the cell will respond to CXCL12. In fact, recent
studies have shown that heterodimerization of these two receptors
modulates the cellular response to CXCL12 [25,28,29].
In this study, we examined the regulation of the CXCL12/
CXCR4/CXCR7 axis and its involvement in the proliferation and
survival of E2-dependent and -independent breast cancer cells. Our
results showed that the E2-dependent up-regulation of CXCL12
and CXCR4 that is associated with a down-regulation of CXCR7
could be pivotal for E2-induced growth of breast cancer cells.
Materials and Methods
1. Antibodies and reagents
The antibodies used for the Western blot assays were rabbit
polyclonal (Rp) antibody against CXCL12 (sc-28876; Santa Cruz
Biotechnology, Heidelberg, Germany), Rp antibody against CXCR4
(ab2074; Abcam Inc., Cambridge, UK), Rp antibody against
CXCR7 (ab12870; Abcam Inc.) and Rp antibody against ERK1
(sc-94; Santa Cruz Biotechnology). The antibodies used for FACS
were murine monoclonal (Mm) antibody anti-human CXCR4 (clone
12G5, R&D Systems) and Mm antibody anti-human CXCR7/
RDC1 (clone 11G8, R&D Systems, Minneapolis, MN, USA).
All reagents used for treatments were purchased from Sigma-
Aldrich (St Louis, MO, USA): 17-b-estradiol (E2), ICI182,.780 (ICI),
ethynyl-estradiol (EE2), Genistein (Gen), Chalcon 4 (inhibitor for
CXCL12) and AMD3100 (inhibitor for CXCR4). CCX771
(inhibitor for CXCR7) was a kind gift from Dr. Mark Penfold
(ChemoCentryx Inc., Mountain View, CA, USA).
2. Cell culture and treatments
The MCF-7 and ZR-75 (ER+) and the MDA-MB231 (ER2)
human breast cancer cell lines were purchased from the American
Type Culture Collection (Manassas, VA, USA). MCF-7, ZR-75
and MDA-MB-231 cells were routinely maintained in DMEM
(Invitrogen, Cergy potoise, France) supplemented with 10% fetal
bovine serum (FBS; Biowest, Paris, France) and antibiotics
(Invitrogen) at 37uCi n5 %C O 2. When steroid treatments were
required, the cells were maintained for 24 h in DMEM without
phenol red (Invitrogen) supplemented with 2.5% dextran-treated
charcoal stripped FBS (dsFBS) prior to the experiments. The
treatments were then performed in DMEM phenol red-free 2.5%
dsFBS during several periods of time with 0.1% ethanol as a
control (EtOH), E2, ICI, EE2, or Gen.
3. RT-PCR assays
A total of 2.5610
5 MCF-7 cells was cultured in 6-well plates and
treated as specified for each experiment. Total RNA from 3
independents wells per condition was extracted using Trizol
TM
(Invitrogen) according to the manufacturer’s instructions. cDNAs
were generated using MMLV Reverse transcriptase (Invitrogen)
and random hexamers (Promega, Madison, WI, USA). Quanti-
tative real-time RT-PCR was performed using the iQ SybrGreen
supermix (BioRad, Hercules, CA, USA) on a BioRad MyiQ
apparatus. The primers (Proligo Primers and Probes, Boulder,
CO, USA) used for cDNA amplification in the quantitative RT-
PCR experiments are described in Table S1.
4. Protein extraction/Western Blot
Cultures were performed in 10 cm diameter plates (80–90%
confluence) and were treated for 48 h to 96 h, as specified for each
experiment. Total proteins were extracted in RIPA buffer (1%
NP40; 0.5% NaDeoxycholate; 1% SDS; in PBS) containing an
anti-protease mix (Complete EDTA-free Antiproteases, Roche,
Meylan, France), and protein concentration was measured using
the Bio Rad DC protein assay kit. The proteins were diluted in
Laemmli buffer and were denatured at 95uC. A total of 30 mgo f
the denatured proteins was then separated on SDS polyacrylamide
gels (10 and 15%), transferred to a polyvinylidene difluoride
membrane (Amersham, Uppsala, Sweden) and probed with
specific antibodies. The immunocomplexes were detected using
an enhanced chemiluminescence system (immune Star, Bio-Rad
Laboratories).
5. ELISA
In all, 7610
4 MCF-7 cells were cultured in 24-well plates in
300 mL of medium. Cell culture supernatants from 6 independent
well per condition were collected after 72 h of treatment.
CXCL12 concentration was determined using the Quantikine
kit (R&D Systems) according to the manufacturer’s instructions.
6. Flow cytometry analysis
In all, 2.5610
5 MCF-7 cells were cultured in 6-well plates and
treated for 48 h with EtOH or 10
28 M E2. For surface CXCR4
and CXCR7 detection, 5610
5 cells were incubated at 4uC for
45 min with 5 mg/ml of nonspecific isotype-matched controls,
mouse to human IgG1 or mouse to human Ig2b or with 5 mg/ml
of the specific monoclonal antibody to either CXCR4 or CXCR7.
The cells were washed twice with PBS and were incubated with
anti-Mouse PE (R-Phycoertythrin Goat anti-mouse) at 4uC for
45 min for nonspecific and CXCR7 binding. The cells were
washed twice with PBS and were resuspended in 500 mL of PBS.
In all, 10
4 of cells from each sample were evaluated for
fluorescence using the Cytomics FC500 apparatus (Beckman
Coulter, Paris, France).
7. Formaldehyde-Assisted Isolation of Regulatory
Elements (FAIRE)
FAIRE was performed as described by Eeckhoute et al. [30].
Briefly, asynchronously growing MCF-7 cells (60–70% confluence)
treated or not for 48 h with 10
28 M E2 were cross-linked with 1%
formaldehyde for 10 min at room temperature. Glycine was added
to a final concentration of 125 mM, and the cells were rinsed with
cold PBS and harvested. The cells were lysed with a solution of 1%
SDS, 10 mM EDTA and 50 mM Tris-HCl (pH 8.1) containing a
protease inhibitor cocktail (Roche) and were then sonicated for
14 min (30-sec on/off cycles) using a Bioruptor (Diagenode, Lie `ge,
Belgium) set at the highest intensity. The soluble chromatin was
subjected to three consecutive phenol-chloroform extractions
(Sigma, P3803) and incubated overnight at 65uC to reverse the
cross-linking. The DNA was then purified using the MinElute
PCR purification kit (Qiagen, Courtaboeuf, France). The relative
enrichment of open chromatin for CXCL12, CXCR4 and CXCR7
proximal promoters was quantified by real-time PCR performed
using the iQ SybrGreen supermix on a BioRad MyiQ apparatus.
The primers used for the quantitative PCR experiments are
described in Table S1.
8. Proliferation assays
All of the experiments involving the transient knockdown of
CXCL12, CXCR4 or CXCR7 expression, the inhibition of
CXCL12, CXCR4 or CXCR7 proteins using inhibitors and the
transient over-expression of CXCR7 were carried out in MCF-7
cells.
Estrogen-Regulation of CXCL12 Pathway
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one day before the siRNA transfection. The cells were then
transfected in triplicate with siRNA targeting human CXCR4 and
CXCR7 (Invitrogen) or human CXCL12 (Qiagen) using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Cells transfected with nonspecific siRNA (Invitrogen)
were used as controls. The day after transfection, the MCF-7 cells
were cultured in 100 mL of medium with EtOH or 10
28 M E2 for
7 days. Every 2 days, the medium was removed, and fresh
treatments were performed. When inhibitors were used, 2500
MCF-7 cells per well were seeded in 96-well plates. The
treatments were then performed in 100 mL of medium with
EtOH or 10
28 M E2 in combination with DMSO, Chalcon 4
(500 nM), AMD3100 (20 mM) or CCX771 (200 nM) for 7 days.
As for the siRNA experiments, the medium was removed and fresh
treatments were performed every 2 days. Relative cell number was
evaluated using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide (MTT; Sigma) assay. In all, 10 mL of the 5 mg/
mL MTT solution was added to the 100 mL of culture medium in
each well, and the cells were incubated for 2 h at 37uC. The
supernatant was removed and the formazan formed was dissolved
in 100 mL of DMSO. The absorbance of each well at 570 nm was
obtained using a microplate reader. For the CXCR7 over-
expression assays, 8000 MCF-7 cells were seeded in 24-well plates
one day before transfection. The cells were then transiently
transfected with 1 mg of pORF9-hCXCR7, an expression vector
containing the human CXCR7 open reading frame (InvivoGen,
San Diego, CA, USA). The day after transfection, the cells were
cultured in 500 mL of medium with EtOH or 10
28 M E2 for 7
days. Total cell number was evaluated by cell count using a Z2
COULTER COUNTER from Beckman Coulter. Each experi-
ment was performed at least three times.
9. Statistical analysis
Statistical analysis was performed using the Student t-test. The
values are provided as the mean 6 the standard error of the mean
(SEM) and were considered statistically significant for p,0.05.
Results
1. The entire CXCL12 axis is an E2 endogenous target in
ER-positive breast cancer cells
The estrogenic regulation of CXCL12 was first confirmed in
MCF-7 cells, a widely used model of ER-positive breast cancer
cells. The cells were stimulated with 10
28 M E2 for different
periods of time, and CXCL12 mRNA was monitored using real-
time quantitative RT-PCR. The positive regulation of CXCL12 in
response to E2-treatment, which occurred in a time-dependent
manner, was confirmed (Fig. 1A). The level of CXCL12 transcripts
significantly increased within 3 h (,3-fold) and reached a
maximum at 48 h (Fig. 1A). Both the basal and E2-induced
expression levels of CXCL12 decreased when the MCF-7 cells were
co-treated with the pure anti-estrogen ICI182,780 (ICI) (Fig. 1B).
Taken together, these findings indicate that ER is involved in basal
and E2-induced CXCL12 gene expression in MCF-7 cells. This E2
induction of CXCL12 was also confirmed at the protein level
using ELISA assay (Fig. 1C). The addition of 10
28 ME 2
significantly increased the secreted levels of the CXCL12 protein
after 48 h of treatment when compared with the control cells
(Fig. 1C).
The E2-regulation of CXCL12 receptors in breast cancer cells is
largely unknown. Thus, CXCR4 and CXCR7 regulation by E2
was verified in our MCF-7 cells. CXCR4 and CXCR7 mRNA
expression were monitored by real-time quantitative RT-PCR and
both CXCR4 and CXCR7 receptors proteins were measured by
FACS assays. Our results demonstrate that E2 stimulates the
expression of CXCR4 mRNA in MCF-7 cells (Fig. 1D). E2-
stimulation of CXCR4 expression was significantly different to the
control cells only after 48 h of E2-treatment. The 3 times
induction was blocked by co-treatment with ICI, confirming that
ER is involved in this regulation (Fig. 1E). In contrast, no effect
was observed when MCF-7 cells were treated with ICI alone
(Fig. 1E). Although earlier studies have shown that CXCR4 is
weakly expressed at the surface of MCF-7 cells [31], our FACS
assays revealed a reproducible and significant increase of CXCR4
protein by 40% after E2 treatment (Fig. 1F). Surprisingly, E2 was
found to trigger a reduction of CXCR7 mRNA levels in MCF-7
cells in a time-dependent manner (Fig. 1G). A significant down-
regulation was observed only 3 h after E2-tretment, whereas the
effect of E2 was reached the maximum after 48 h of treatment.
This E2 effect was abolished when MCF-7 cells were co-treated
with the pure anti-estrogen ICI, suggesting that ER is involved in
this down-regulation (Fig. 1H). No effect was observed when
MCF-7 cells were treated with ICI alone. The FACS analysis
established that CXCR7 protein expression on the cell surface of
E2-treated MCF-7 cells was significantly reduced by 40 to 45%
compared with that in the solvent-treated control cells (Fig. 1I).
To investigate whether the differential E2-regulation of CXCR4
and CXCR7 could be extended to other breast cancer cell lines,
we analyzed the expression of the components of the CXCL12
axis in ER-positive ZR-75 (Fig. 2A) and ER-negative MDA-MB-
231 (Fig. 2B) breast cancer cell lines. As expected, we found a
similar profile of regulation by E2 for CXCL12, CXCR4 (which are
induced) and CXCR7 (which is repressed) mRNA in ZR-75
whereas these genes were not sensitive to E2 in MDA-MB-231
cells.
2. Effect of xeno-estrogens on the CXCL12/CXCR4/CXCR7
axis regulation in MCF-7 cells
E2-target genes can be regulated differently by exogenous ER-
ligand depending on the cell and promoter contexts. To examine
whether the CXCL12 signaling axis may be differentially
regulated by ER ligands in breast cancer cells, we examined the
effects of several xeno-estrogens on the expression of CXCL12,
CXCR4 and CXCR7 in MCF-7 cells. Using real-time RT-PCR,
we assessed the effect of agonistic xeno-estrogens such as ethinyl-
estradiol (EE2) and genistein (Gen) which are used in hormonal
therapy. Dose-effect experiments were carried out and compared
with 10
28 M of E2, the natural ligand (Fig. 3).
As expected, EE2 behaved as E2 as it induced significantly the
expression of CXCL12 and CXCR4 mRNAs, whereas it decreased
CXCR7 mRNA expression (Fig. 3A). However, EE2 was much
more potent since the maximal response obtained with EE2
required a concentration 10 to 100-fold lower than that required
for E2 maximal effect. The phytoestrogen genistein also showed
estrogenic properties on the CXCL12 axis (Fig. 3B). Nevertheless,
high concentrations (from 10
26 M and 5610
26 M) of ligand were
required to significantly up regulate CXCL12 or down regulate
CXCR7 expression. On the other hand, lower concentrations (from
10
28 M) of genistein were sufficient to stimulate CXCR4 gene
expression.
3. E2 modulates the chromatin structure of the CXCL12,
CXCR4 and CXCR7 promoters
The level of chromatin compaction appears to be well
correlated with its activity. Recent studies have reported that
active transcriptional regulatory sites are present within open
Estrogen-Regulation of CXCL12 Pathway
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[30]. These nucleosome-depleted genomic regions can be enriched
from chromatin preparations using the FAIRE method [32].
Thus, FAIRE was used to monitor the effect of E2 on the
chromatin structure of the CXCL12, CXCR4 and CXCR7
promoters in MCF-7 cells. E2 treatment (10
28 M) for 48 h
resulted in an 8-fold increase in the amount of DNA correspond-
ing to the CXCL12 and CXCR4 promoters in the FAIRE samples,
indicating an opening of the chromatin at these two promoters due
to E2 stimulation (Fig. 4A). In contrast, FAIRE enrichment of the
CXCR7 promoter was significantly decreased (,60%) after E2
treatment of MCF-7 cells (Fig. 4A), suggesting that E2 triggers the
chromatin containing the CXCR7 promoter to be remodeled in a
more condensed structure.
Zhu et al. showed recruitment of ERa to the CXCL12 proximal
promoter, which harbors an estrogen response element (ERE) half
site [33]. Chromatin immunoprecipitation (ChIP) assays per-
formed in this study, however, did not reveal any stable or
reproducible recruitment of ERa to the CXCL12, CXCR4 or
CXCR7 proximal promoters (up to 3 kb) (data not shown).
Moreover, these proximal promoters of the CXCL12, CXCR4 or
CXCR7 genes were not sensitive to E2 in luciferase-reporter assays
performed in MCF-7 cells (data not shown). Recent studies on ER
recruitment to the genome of breast cancer cells indicated that ER
preferentially regulates its target genes by binding distal regulatory
elements [34]. These distal regulatory sites can interact with the
promoters of E2 target genes due to chromatin looping [35]. An
examination of ChIP-chip data for ER from MCF-7 cells revealed
Figure 1. Regulation of CXCL12 signalization expression by E2 in MCF-7 cells. Cells were cultured as described in ‘‘Materials and Methods’’
and treated with E2 or ICI184,780 (ICI) using EtOH as vehicle. The vehicle-only treatment served as a control. The mRNA levels of CXCL12 (A and B),
CXCR4 (D and E) and CXCR7 (G and H) were quantified by real-time PCR analysis of cells treated for different periods of time with 10
28 M E2 (A, D and
G) or cells treated for 48 h with 10
28 M E2 alone, 10
26 M ICI alone or both E2 and ICI (B, E and H). The real-time PCR results were normalized against
the internal control GAPDH and expressed as the mean CXCL12, CXCR4 or CXCR7/GAPDH mRNA ratio 6 SEM of at least three independent
experiments. Protein levels of CXCL12 (C), CXCR4 (F) and CXCR7 (I) was assayed. Secreted CXCL12 protein levels after treatment with EtOH or 10
28 M
E2 for 48 h were determined by ELISA, and the values were normalized relative to the total protein concentration (C). The expression of CXCR4 and
CXCR7 at the surface of MCF-7 cells was measured by flow cytometry after treatment with EtOH or 10
28 M E2 for 48 h (F, I). Representative data from
at least three experiments performed in duplicate are shown. Asterisks or different lowercase letters indicate significant differences (p,0.05) between
the control and treated cells.
doi:10.1371/journal.pone.0020898.g001
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CXCL12, CXCR4 and CXCR7 genes where ER could bind
(Fig. 4B). These three gene regions contain several ER-binding
sites for which the closest transcription start sites (TSS) are those of
CXCL12, CXCR4 or CXCR7, which is a hallmark of E2-regulated
genes [36]. The distance between the TSSs and the ER binding
sites ranges from 20 to 250 kb, which is within the range of
previously described active ER-bound enhancers [35,37,38,39].
We have identified only one full ERE motif within the binding
region, which is located 234 kb upstream from the TSS of the
CXCL12 gene (Fig S1), and several half ERE motifs in
combination with SP1 and AP1 motifs within the genomic regions
of the CXCR4 and CXCR7 genes (Fig S1).
4. Relationship between the CXCL12 axis and the basal
and E2-dependent growth of MCF-7 cells
CXCL12 is known to promote proliferation and survival of
cancer cells in an autocrine and paracrine manner. Its regulation
by E2 is also regarded as having an important role in the
proliferative response to this hormone. However, the involvement
of the entire CXCL12 signaling axis in cell growth is poorly
documented. Specific siRNAs directed against CXCL12, CXCR4
and CXCR7 were used to assess the importance of this axis in the
basal and E2-dependent growth of breast cancer cells. Quantita-
tive RT-PCR and Western blot assays showed a knockdown
efficiency of nearly 50%–60% compared with that of the control
siRNA (Fig. 5A and 5B). MCF-7 cells transfected with the specific
siRNAs were then exposed to 10
28 M E2 or solvent for 7 days,
and the total cell number was quantified by MTT assay (Fig. 5C).
The number of MCF-7 cells transfected with the specific siRNAs
was reduced 45 to 60% compared with that of MCF-7 cells
transfected with the siRNA control, suggesting that all three
components of the CXCL12 axis are necessary for basal cell
growth (Fig. 5C).
As expected, when the cells were transfected with the control
siRNA, E2 treatment significantly increased the total cell number
(1.63-fold) (Fig. 5C). When MCF-7 cells were transfected with
siRNA directed against CXCL12, the total cell number in the
presence of E2 reached only 45% of the control. Similarly,
targeting CXCR4 decreased the total cell number in the presence
of E2 (55%). In contrast, when decreasing CXCR7 expression by
specific siRNA, the total cell number was comparable to E2-
treated cells transfected with control siRNA (Fig. 5C).
To confirm these results, the effects of Chalcon 4, AMD3100
and CCX771, which are specific inhibitors of CXCL12, CXCR4
and CXCR7, respectively, were tested. The relative cell number
was evaluated after 7 days of treatment with or without E2 in
combination with DMSO or the different inhibitors. The results
obtained with each specific inhibitor were generally similar to
those obtained with each specific siRNA (Fig. 5C and 5D). The
basal growth rate of MCF-7 cells was reduced after treatment with
the Chalcon 4, AMD3100 or CCX771 inhibitors (Fig. 5D). In the
presence of E2, Chalcon 4 and AMD3100 caused a significant
reduction in cell growth, whereas CCX771 had no effect (Fig. 5D).
Furthermore, the impact of CXCR7 over-expression on MCF-7
cell growth was tested. Transient transfection of an expression
Figure 2. Regulation of CXCL12, CXCR4 and CXCR7 mRNA expressions by E2 in ZR-75 and MDA-MB-231 cells. CXCL12, CXCR4 and CXCR7
mRNA were assessed by quantitative real time PCR after 48 h treatment of ZR-75 (A) or MDA-MB-231 (B) cells to EtOH (2) or to10
28 ME 2( +).
Transcript levels were normalized against GAPDH mRNA and data were calculated as percentage of the E2 effect. Data are from triplicate samples and
are representative of three separate experiments. Asterisk indicates significant differences (p,0.05) between the control and ligand treated cells.
doi:10.1371/journal.pone.0020898.g002
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produce elevated levels of CXCR7 protein (Fig. 6A), was sufficient
to increase basal cell growth (Fig. 6B). Interestingly, this increase in
CXCR7 expression significantly reduced the E2-induced growth
effect (Fig. 6B). Thus, these findings suggest that although CXCR7
is likely involved in basal cell growth, the increased expression of
this receptor may be unfavorable to the growth effect of E2 on
MCF-7 cells.
Discussion
The chemokine CXCL12 is thought to mediate the growth
effect of E2 in ER-positive ovary and breast cancer cells [8].
CXCL12 binds to two G protein-coupled receptors, CXCR4 and
CXCR7, which can modulate the response to CXCL12 by
forming both homodimers and heterodimers. The regulation of
CXCR4 and CXCR7 by estrogens and their involvement in the
E2-dependent growth of breast cancer cells, however, have not
been well characterized.
Our study showed that all of the components of the CXCL12
axis are targets of E2 in ER-positive but not in ER-negative breast
cancer cells. Interestingly, our results showed that E2 differentially
regulates both CXCL12 receptors. While CXCR4 expression was
up-regulated by E2, CXCR7 expression was down-regulated by
E2. A previous study conducted in Ishikawa endometrial
adenocarcinoma cells have suggested that E2 could induce
CXCR4 expression at the transcriptional level [15]. Regarding
breast cancer cells, CXCR4 was also proposed to be induced by
E2 but only through post-translational effects in a particular model
of MCF-7 cells overexpressing HER2 [40]. Thus, we are the first
to demonstrate that CXCR4 transcription can be induced by E2
stimulation in breast cancer cells. Moreover, to the best of our
knowledge, the E2-induced down-regulation of CXCR7 has not
been previously reported. The anti-estrogen ICI completely
suppressed these effects by E2, indicating the importance of the
classical nuclear ERs in the regulation of the entire CXCL12
signaling axis. It should be noticed that the discrepancy in the fold
change factors observed between the chemokine receptors mRNA
and protein levels, may argue for the consequence of additional
control mechanisms besides transcription. This may be attributed
to differences in the mRNA and protein turn over or could
originate from different translational regulation. Moreover,
following E2-treatment, the increased secretion of CXCL12 may
modulate the internalization of both CXCR4 and CXCR7; and
consequently may influence the expression of the chemokine
receptors at the cell surface [22].
As expected, some xeno-estrogens such as EE2 (used in
contraceptive pills) or genistein (a phytoestrogen found in food
Figure 3. Xeno-estrogen effects on the expression of CXCL12, CXCR4 and CXCR7 in MCF-7 cells. The levels of the CXCL12, CXCR4 and
CXCR7 transcripts were assessed by quantitative real-time PCR in MCF-7 cells treated under various conditions for 48 h. Treatment with EtOH and
10
28 M E2 served as the negative and positive controls, respectively. In each experimental assay, the cells were exposed to different concentrations
of 17 a-ethynyl-estradiol (EE2) (A) and Genistein (Gen) (B). Transcript levels were normalized against GAPDH mRNA, and data were calculated as
percentage of the E2 effect for each experiment. Significant differences (P,0.05) are indicated by different lowercase letters.
doi:10.1371/journal.pone.0020898.g003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20898Figure 4. Impact of E2 treatment on the chromatin structure of the CXCL12, CXCR4 and CXCR7 promoters. (A) FAIRE assays were
performed on MCF-7 cells exposed to either ETOH (2)o r1 0
28 ME 2( +) for 48 h. Real-time PCR was performed to monitor enrichment of the DNA
corresponding to the proximal promoters of the CXCL12, CXCR4 and CXCR7 genes relative to input chromatin. The data are from triplicate samples
and are representative of three separate experiments. Asterisks indicate significant differences (p,0.05) between the control and treated cells. (B) The
Integrated Genome Browser (Affymetrix) was used to visualize ER-binding sites in the regions surrounding the CXCL12, CXCR4 and CXCR7 genes. Raw
ChIP-chip data for ER and high confidence ER-binding sites called using the MAT algorithm are shown [34,55]. The numbered ER-binding sites
correspond to bound regions in which the closest TSS is that of CXCL12, CXCR4 or CXCR7. Arrows indicate the orientation of the CXCL12, CXCR4 and
CXCR7 genes.
doi:10.1371/journal.pone.0020898.g004
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20898Figure 5. Involvement of CXCL12, CXCR4 and CXCR7 in the E2-dependent and -independent growth of MCF-7 cells. siRNA directed
against CXCL12, CXCR4 or CXCR7 was transfected into MCF-7 cells treated with EtOH (2)o r1 0
28 ME 2( +). (A) After 48 h, the levels of the CXCL12,
CXCR4 and CXCR7 transcripts were assessed by quantitative PCR and normalized against GAPDH mRNA. The results were compared with those
obtained from MCF-7 cells transfected with a nonspecific siRNA control. (B) Total protein was extracted from MCF-7 cells, and the levels of CXCL12,
CXCR4 and CXCR7 were analyzed by Western blotting. (C) To determine the growth rate of the MCF-7 cells, the siRNA-transfected cells were treated
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20898supplements), acted like E2 on the entire CXCL12 axis, with
however different dose-effect profiles. These different dose-effects,
notably regarding the discrepancies of genistein effect, might be
linked to the importance of ER subtypes involved in the
transcriptional regulations observed. Indeed, genistein is more
ERb than ERa selective and it is worth to note that there is very
low level of ERb expression in MCF-7 cells.
The FAIRE experiments confirmed the differential regulation of
CXCR4 and CXCR7 by E2 and showed that this hormonal
treatment affects the condensation state of the chromatin
containing the proximal promoters of the CXCL12, CXCR4 and
CXCR7 genes. Modification of the chromatin structure has been
shown to correlate with the transcriptional potential of regulatory
elements, and could suggest epigenetic modifications induced by
E2 treatment.
The direct interaction of ER with the CXCL12, CXCR4 and
CXCR7 genes was assessed using traditional ChIP and luciferase-
reporter assays of the proximal promoter regions (up to 3 kb) in
Figure 6. Impact of CXCR7 over-expression on the E2-dependent and -independent growth of MCF-7 cells. MCF-7 cells were transiently
transfected with either a control expression vector or one containing the human CXCR7 open reading frame. (A) Total protein extracts were prepared
48 h after transfection, and a Western blot analysis was performed to confirm CXCR7 over-expression. (B) Transfected cells were cultured in the
presence of EtOH (2)o r1 0
28 ME 2( +) for seven days. E2-dependent and E2-independent cell growth rates were then evaluated by cell count of
three independent experiments (n=3). The results are expressed as a percentage of the relative cell number obtained from control cells treated with
E2 (considered as 100%). Significant differences (p,0.05) between transfected cells in the absence of E2 are indicated by an asterisk and between
transfected cells in the presence of E2 by a sharp symbol. (C) A proposed model for the involvement of the CXCL12 signaling axis in E2-dependent
and -independent cell growth is shown. The binding of CXCL12 to CXCR4 and CXCR7 leads to the stimulation of cell growth through diverse
pathways [28]. CXCR7 can also modulate CXCL12 availability by removing the chemokine from the extracellular space (left panel). Estrogens could
stimulate cell growth by favoring the activation of CXCL12 through CXCR4 and reducing the expression of CXCR7 (right panel).
doi:10.1371/journal.pone.0020898.g006
with EtOH (2E2) or 10
28 ME 2( +E2) for seven days. E2-dependent and -independent cell growth were evaluated using MTT assays of three
independent experiments (n=6). The results are expressed as a percentage of the relative cell number obtained from cells transfected with the
control siRNA and treated with EtOH (considered as 100%). Significant differences (p,0.05) between transfected cells in the absence of E2 are
indicated by an asterisk and between transfected cells in the presence of E2 by a sharp symbol. (D) The effects of specific inhibitors for CXCL12
(Chalcon 4), CXCR4 (AMD3100) or CXCR7 (CCX771) were measured after treatment of MCF-7 cells with either EtOH (2E2) or 10
28 ME 2( +E2) for 7
days. DMSO (vehicle) was used as the control. E2-dependent and E2-independent cell growth were then evaluated by MTT assays of three
independent experiments (n=6). The results are expressed as a percentage of the relative cell number obtained from cells treated with the vehicle
control (considered as 100%). Significant differences (p,0.05) between treated cells in the absence of E2 are indicated by an asterisk and between
treated cells in the presence of E2 by a sharp symbol.
doi:10.1371/journal.pone.0020898.g005
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sites or direct ER action at the proximal promoters of the CXCL12,
CXCR4 and CXCR7 genes (data not shown). Nevertheless, the
ChIP-chip analysis showed significant ER binding sites located
20–250 kb distal to the TSS of the CXCL12, CXCR4 and CXCR7
genes. These binding sites are always found closer to the TSS of
the target gene than to the TSS of any other contiguous genes in
the region. These results are in good agreement with recently
published genome-wide studies showing that more than 90% of
the mapped ER-binding sites are located far from the TSS of
target genes and within intronic or distal regions (.5 kb from the
59 and 39 ends of adjacent transcripts). Moreover, the vast majority
of these binding site sequences harbor full EREs, ERE-like or half
ERE motifs [34,41,42], which were also found for the ER-binding
sites associated with the CXCL12, CXCR4 and CXCR7 genes.
Altogether, these finding suggest that direct interaction of ER with
the CXCL12, CXCR4 and CXCR7 genes could occur primarily at
these multiple distal sites, which would then allow ER to modulate
transcription initiation at the target gene promoters by chromatin
looping. Chromatin interactions have recently been proposed to
represent a major mechanism for regulating gene transcription in
mammals [35]. Accordingly, ER has been reported to function by
extensive chromatin looping to provide a collaboration between
outlying ER binding sites and other regulatory elements within
proximal promoters that could be important for cell- and
promoter-specific transcriptional regulation of target genes
[35,38].
E2 induces the expression of CXCL12 and CXCR4 and
represses the expression of CXCR7 both at the transcriptional and
translational levels, suggesting a functional regulation. The positive
regulation of CXCL12 and CXCR4, which can induce cell
proliferation and survival, has been well correlated with the
growth effect of E2 on breast cancer cells. In contrast, the impact
of the negative regulation of CXCR7 by E2 remains unclear.
Recent studies have suggested that CXCR7 also contributes to cell
proliferation or survival [23,24,27,43]. Thus, the down regulation
of its expression by E2 signaling would not be compatible with the
growth effect of that hormone. We therefore examined the effect
of the partial down-regulation or the inhibition of each component
of the CXCL12 axis on the proliferation and survival of MCF-7
cells in the presence and absence of E2. Our results showed that
each component of the CXCL12 axis contributes to the basal
growth rate of MCF-7 cells. Each component of the axis, however,
appears to contribute differently to the E2-dependent growth of
MCF-7 cells. In agreement with a previous study [8], we also
observed that reducing CXCL12 expression or inhibiting its
activity significantly limits the E2-induced growth effect. Similarly,
inhibition by CXCR4-specific siRNA or by AMD3100, a specific
inhibitor of this receptor, significantly decreased the stimulation of
cell growth by E2. Taken together, these observations indicate that
enhancement of the expression of CXCL12 and CXCR4 by E2
may constitute a molecular mechanism by which breast cancer
cells proliferate in response to that hormone. Although in this
study, we measured the global effect of E2 on cell growth which is
a resultant of both cell survival and proliferation, future work by
testing cell cycle distribution would be necessary to determine the
specific cell cycle phase.
Several studies have demonstrated that CXCR7 does not
function like a classical GPCR, and this receptor could mediate
intracellular CXCL12 signaling via a different mechanism than
that of the CXCL12-CXCR4 complex [28,43,44]. Although the
reduction of CXCR7 expression or inhibition of its activity, which
reproduce the natural effect of that hormone, did not modify the
E2-dependent proliferation of MCF-7 cells, its over-expression in
MCF-7 cells affected basal cell growth positively and E2-
dependent induction of cell growth negatively. These observations
suggest that the E2-induced down-regulation of CXCR7 could be
associated with the effect of this hormone on breast cancer cell
growth. Thus, the contribution of CXCR7 to cell proliferation
would be different depending on whether cell proliferation was
promoted by E2 or by other growth factors. Recently, Luker et al.
showed that CXCR7 can modulate the availability of CXCL12 by
its removal from the extracellular space [45]. This mechanism
could limit CXCL12 signaling via CXCR4. Thus, a decrease in
the cell surface expression of CXCR7 and an augmentation of
CXCL12 secretion and CXCR4 expression by E2 could promote
cell proliferation by favoring CXCL12 signaling through CXCR4
(Fig. 6C). Nevertheless, this particular role for the scavenger
receptor, which has also been reported in other cancer cell and
animal models, might not represent the only mode of action for
CXCR7. Indeed, the CXCR4 and CXCR7 receptors appear to
be constitutively able to form homo- and heterodimers that could
modulate the sensitivity and response to the CXCL12 ligand
[46,47,48]. Furthermore, the formation of homo- or heterodimers
seems to depend primarily on the expression level of both
receptors in the cells [25]. The differential regulation of both
CXCL12 receptors by estrogens would therefore have important
consequences. The expression level of CXCR7 could serve as an
important element that facilitates CXCR4 in the signal transduc-
tion of CXCL12. By specifically modifying CXCR4 positively and
CXCR7 negatively, we speculate that E2 could modulates the
ratio of the two GPRCs, promoting the formation of CXCR4/
CXCR7 heterodimers or CXCR4/CXCR4 homodimers on the
surface of MCF-7 cells, which would create an environment
favorable to the stimulation of cell growth.
Expression profiling studies showed that the highest ER
expression levels was found in tumors associated with the most
favorable survival outcomes [49,50,51]. The expression of ERs in
breast cancer cells prevents the acquisition of a high potential for
the migration and invasion of tumor cells by promoting the
maintenance of these cells in a differentiated state [5,6]. In
addition to its involvement in cell proliferation, the signaling axis
of CXCL12 is strongly associated with cell migration [13,18,20].
Recently, the autocrine/paracrine CXCL12 stimulation of cancer
cells was reported to restrain their migration behavior. The loss of
local CXCL12 expression may then be necessary to allow the cells
to spread within the organism toward endocrine sources of
CXCL12 [52,53,54]. During cancer progression, the hormonal
control of the CXCL12 signaling axis in breast cancer cells may
therefore play major roles in tumor growth and the suppression of
the invasion potential of cancer cells.
In conclusion, our study demonstrated that the components of
the entire CXCL12 signaling axis are targeted by E2 in breast
cancer cells. The E2-induced up-regulation of the chemokine
CXCL12 and its receptor CXCR4 and down-regulation of
CXCR7 could be associated with the effect of estrogens on the
growth of breast cancer cells.
Supporting Information
Figure S1 Sequence analysis and localizations of ER
binding sites in the distal genomic regions of CXCL12,
CXCR4 and CXCR7 genes. Genomic sequence regions
corresponding to which significant ER binding sites are identified
by ChIP-chip for CXCL12 gene (on chromosome 12), CXCR4
and CXCR7 (on chromosome 2) are shown. As also indicated in
Fig. 4 B, sequences of the six ER binding sites for CXCL12 gene
located at 234 kb upstream and 83 kb, 125 kb, 147 kb, 208 kb
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PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20898and 210 kb downstream of TSS.; as well as the two sites found for
CXCR4 gene located at 97 kb and 210 kb upstream from TSS;
and the six sites found for CXCR7 gene located at 23 kb, 99 kb,
124 kb, 163 kb, 200 kb and 256 Kb upstream from TSS are
indicated. Using the TESS web based software (Transcription
Element Search System; www.cbil.upenn.edu/cgi-bin/tess), the
putative binding sites for transcription factors were examined in
these genomic regions. In addition to only one full ERE motif
found within the binding region located at 234 kb upstream from
the TSS of CXCL12 gene, principally half ERE, SP1 and AP1
motifs were found within these genomic regions.
(TIF)
Table S1 Primers sequences.
(TIF)
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